The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α

Pediatric inflammatory bowel disease (PIBD) is a globally increasing chronic inflammatory disease associated with an imbalanced intestinal microbiota and treated with several treatment options, including anti-tumor necrosis factor alpha (TNF-α), such as infliximab (IFX). Up to half of the patients d...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-04, Vol.12 (1), p.6654-6654, Article 6654
Main Authors: Ventin-Holmberg, Rebecka, Höyhtyä, Miikka, Saqib, Schahzad, Korpela, Katri, Nikkonen, Anne, Salonen, Anne, de Vos, Willem M., Kolho, Kaija-Leena
Format: Article
Language:English
Subjects:
631/326/2565/2134
692/53
Abundance
Bacteria - genetics
Child
Crohn Disease - drug therapy
Digestive system
Feces
Gastrointestinal Microbiome
Gastrointestinal tract
Humanities and Social Sciences
Humans
Inflammatory bowel disease
Inflammatory bowel diseases
Inflammatory Bowel Diseases - drug therapy
Inflammatory Bowel Diseases - microbiology
Infliximab
Infliximab - therapeutic use
Intestinal microflora
Intestine
Leukocyte L1 Antigen Complex
Microbiota
Monoclonal antibodies
multidisciplinary
Necrosis
Patients
Pediatrics
Relative abundance
Science
Science (multidisciplinary)
Tumor Necrosis Factor-alpha - drug effects
Tumor Necrosis Factor-alpha - therapeutic use
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pediatric inflammatory bowel disease (PIBD) is a globally increasing chronic inflammatory disease associated with an imbalanced intestinal microbiota and treated with several treatment options, including anti-tumor necrosis factor alpha (TNF-α), such as infliximab (IFX). Up to half of the patients do not respond to the drug and there are no methods for response prediction. Our aim was to predict IFX response from the gut microbiota composition since this is largely unexplored in PIBD. The gut microbiota of 30 PIBD patients receiving IFX was studied by MiSeq sequencing targeting 16S and ITS region from fecal samples collected before IFX and two and six weeks after the start of treatment. The response to IFX induction was determined by fecal calprotectin value 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-10548-7